HUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. lifted its holdings in HUTCHMED (China) Limited (NASDAQ:HCM) by 99.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,724 shares of the company’s stock after purchasing an additional 24,245 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in HUTCHMED were worth $952,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in HCM. Rhumbline Advisers lifted its position in HUTCHMED by 8.1% during the 2nd quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock worth $129,000 after acquiring an additional 564 shares during the period. Vanguard Personalized Indexing Management LLC lifted its position in HUTCHMED by 9.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company’s stock worth $226,000 after acquiring an additional 1,168 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in HUTCHMED by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock worth $117,000 after acquiring an additional 2,321 shares during the period. Blue Trust Inc. lifted its position in HUTCHMED by 638.2% during the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock worth $69,000 after acquiring an additional 3,057 shares during the period. Finally, Hennion & Walsh Asset Management Inc. lifted its position in HUTCHMED by 8.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 61,887 shares of the company’s stock worth $1,060,000 after acquiring an additional 4,877 shares during the period. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Stock Performance

Shares of HUTCHMED stock opened at $18.43 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81. HUTCHMED has a twelve month low of $11.93 and a twelve month high of $21.92. The business has a 50-day moving average price of $18.80 and a 200 day moving average price of $18.52.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. The Goldman Sachs Group boosted their price objective on HUTCHMED from $17.00 to $19.00 and gave the company a “neutral” rating in a report on Thursday, August 1st. StockNews.com cut HUTCHMED from a “buy” rating to a “hold” rating in a report on Monday, November 18th.

HUTCHMED Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.